HIV/AIDS Topics Gilead and Tibotec To Develop New Combo Pill
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 05 July 2011 12:08
- Written by Tad Kepley
Gilead Sciences and Tibotec Pharmaceuticals announced a collaboration to develop a fixed-dose combination pill containing the protease inhibitor darunavir (Prezista) plus the novel boosting agent cobicistat.
Study Sheds Light on Residual Viral Load
- Details
- Category: Search for a Cure
- Published on Tuesday, 05 July 2011 12:04
- Written by Liz Highleyman
Residual low-level HIV plasma viremia correlates with size of the CD4 T-cell reservoir, but not immune activation markers. 
New HRSA Guide for HIV/AIDS Clinical Care
- Details
- Category: HIV Treatment Guidelines
- Published on Tuesday, 28 June 2011 06:37
- Written by Tad Kepley
An updated version of the Health Resources and Services Administration (HRSA) Guide for HIV/AIDS Clinical Care is now available free online.
HIV Coreceptor Tropism Affects Treatment Outcomes
- Details
- Category: HIV ART Response Predictors
- Published on Tuesday, 28 June 2011 06:44
- Written by Liz Highleyman
HIV strains that use the CXCR4 co-receptor are associated with higher risk of virological failure on antiretroviral therapy than those using CCR5, according to a recent Spanish study. 
Elevated CD8 Cell Count Predicts HIV Treatment Failure
- Details
- Category: HIV ART Response Predictors
- Published on Tuesday, 21 June 2011 02:27
- Written by Liz Highleyman
Tobira Starts Phase 2b Cenicriviroc Trial
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 28 June 2011 06:41
- Written by Tobira
Tobira Therapeutics recently opened a middle-phase trial of its dual CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Older HIV+ People May Benefit from Earlier ART
- Details
- Category: When to Start ART?
- Published on Tuesday, 07 June 2011 02:45
- Written by Liz Highleyman
Starting antiretroviral treatment at higher CD4 T-cell counts predicted better long-term immune recovery in a large U.S. cohort, while age over 50 years and hepatitis B or C coinfection were linked to smaller CD4 cell gains.
Web Design and Development by